Navigation Links
Amira Pharmaceuticals to Present Preclinical Data on AM152 , an LPA1 Receptor Antagonist, at the Annual Meeting of the American Thoracic Society
Date:5/11/2011

SAN DIEGO, May 11, 2011 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that it will present preclinical data on AM152, an LPA1 receptor antagonist, during the Annual Meeting of the American Thoracic Society (ATS) in Denver, Colorado.  The poster, titled "The LPA1 Antagonist, AM152, Is Efficacious in Mouse Models of Fibrosis," will be presented on Monday, May 16, from 8:15 to 10:45 a.m. MDT.

The LPA1 receptor is part of the lysophosphatidic acid signaling pathway.  Under pathological conditions, LPA1 is associated with a breakdown of the endothelial barrier and the stimulation of fibroblast recruitment, proliferation and transformation, resulting in excessive deposition of extracellular matrix proteins.  Studies have shown that the LPA1 receptor may play a role in several fibrotic diseases, including Idiopathic Pulmonary Fibrosis (IPF).

"Our preclinical data demonstrate that AM152 reduces pro-fibrotic activity by fibroblasts in vitro and tissue fibrosis in numerous in vivo models," said Gretchen Bain, Ph.D., Executive Director of Biology.  "AM152 reduces fibrosis in multiple tissue types thus providing a strong rationale for clinical exploration in patients suffering from a variety of fibrotic diseases."

Bob Baltera, Chief Executive Officer, added, "Our lead LPA1 program, AM152, is one of the cornerstones for Amira's future.  As previously disclosed, we look forward to initiating Phase 2a clinical studies in patients suffering from fibrotic disease in order to explore the therapeutic benefit of this compound."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.  Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions.  Our team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases.  Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.  For more information, visit www.amirapharm.com.

Media Contact
Ian Stone
Russo Partners
Tel: +1 619 528 2220
ian.stone@russopartnersllc.com


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
2. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
3. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
4. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
5. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
6. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
7. Visage Imaging Releases Amira 5.3
8. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
9. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
10. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
11. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... and Markets has announced the addition of the "Contraceptives - Global ... ... US, Canada , Japan , ... America , and Rest of World. Annual estimates and forecasts are ... is provided for these markets. Market data and analytics are derived from ...
(Date:2/17/2017)... According to a new market research report ... Application (Cleanroom Monitoring, Contamination Monitoring of Liquids), and End User (Healthcare ... the market is expected to reach USD 330.6 Million by 2021 ... from 2016 to 2021. Continue Reading ... ...
(Date:2/17/2017)... Research and Markets has announced the addition of ... to their offering. ... provides separate comprehensive analytics for the US, Canada , ... Asia-Pacific , and Rest of World. Annual estimates and forecasts are ... is provided for these markets. Market data and analytics are derived from ...
Breaking Medicine Technology:
(Date:2/18/2017)... PA (PRWEB) , ... February 17, 2017 , ... Butler ... about the Stannah Stairlift and other Butler products. Ken was impressed with the ... and agreed to endorse the product on his show. This endorsement by Ken ...
(Date:2/18/2017)... ... February 18, 2017 , ... A ... information and contact points to easily connect elderly veterans of America's armed forces ... elder-care funding. It also conveys material on this year's increase in the Veterans ...
(Date:2/17/2017)... ... February 17, 2017 , ... Wells ... the electronic prescribing of controlled and non-controlled substances plus the ability to manage ... in the United States now accept electronic prescriptions, according to the Office of ...
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective Action & Preventive ... FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... and preventive action (PA)? , The methods share techniques and tools but they ...
(Date:2/17/2017)... ... February 17, 2017 , ... MAP Revenue ... that Karen Pilley has been promoted to Chief Executive Officer. , The ... paradigm – a shift that demands the transition from pay-for-service to pay-for-performance models. ...
Breaking Medicine News(10 mins):